Anticoagulation in Post MI LV Thrombus Trial in Nepal
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.
Also called NCT05794399
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 196 participants
- Sponsor
- Shahid Gangalal National Heart Centre
- Registry
-
NCT05794399
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Nepal
- Registry status
- Recruiting
Technical summary
Registry record NCT05794399. Randomized; single masking; primary purpose treatment. Start 2023-06-19 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anticoagulation in Post MI LV Thrombus Trial in Nepal
- Acronym
- WaRMIN
- Condition
- Left Ventricular Thrombus
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Shahid Gangalal National Heart Centre
Record details
- Record id
cardio:ct-nct05794399- Content hash
2d9aae3a748c5b076a3f1b8a401c45ce00fd084539721c7c4db8034d1d95e3e4